Amir Nashat Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Amir Nashat.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Amir Nashat. Amir Nashat is Director in aTYR PHARMA INC ($LIFE) and Director in BIND Therapeutics, Inc ($BIND) and Director in FATE THERAPEUTICS INC ($FATE) and Director in SELECTA BIOSCIENCES INC ($SELB) and Director in Receptos, Inc. ($RCPT) and Director in Syros Pharmaceuticals, Inc. ($SYRS) and Director in Metacrine, Inc. ($MTCR) and Director in Morphic Holding, Inc. ($MORF) and Director in Scholar Rock Holding Corp ($SRRK).
Latest Insider Trading Transactions of Amir Nashat
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, LIFE, BIND, FATE, MTCR, MORF, RCPT, SRRK, SELB, SYRS
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 2021 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | A | 64.79 | 12,000 | 777,480 | 12,000 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 15,118 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 216,106 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 20,585 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 451,666 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 128,201 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Option Exercise | C | 0.00 | 1,832,582 | 0 | 0 | |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 15,118 | 0 | 178,942 | 163.8 K to 178.9 K (+9.23 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 216,106 | 0 | 2,715,316 | 2.5 M to 2.7 M (+8.65 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 20,585 | 0 | 163,824 | 143.2 K to 163.8 K (+14.37 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 451,666 | 0 | 2,499,210 | 2 M to 2.5 M (+22.06 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 128,201 | 0 | 143,239 | 15 K to 143.2 K (+852.51 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | C | 0.00 | 1,832,582 | 0 | 2,047,544 | 215 K to 2 M (+852.51 %) |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | P | 13.00 | 15,038 | 195,494 | 15,038 | 0 to 15 K |
| Sep 22 2020 | MTCR | Metacrine, Inc. | Nashat Amir | Director | Buy | P | 13.00 | 214,962 | 2,794,506 | 214,962 | 0 to 215 K |
| Jun 19 2020 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | A | 22.96 | 12,000 | 275,520 | 12,000 | |
| Jun 18 2020 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | A | 17.65 | 13,000 | 229,450 | 13,000 | |
| Jun 11 2020 | SYRS | Syros Pharmaceutic ... | Nashat Amir | Director | Option Exercise | A | 9.17 | 17,500 | 160,475 | 17,500 | |
| Jun 11 2020 | SYRS | Syros Pharmaceutic ... | Nashat Amir | Director | Option Exercise | A | 9.17 | 17,500 | 160,475 | 17,500 | |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 299 | 6,736 | 11,034 | 11.3 K to 11 K (-2.64 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 302 | 6,805 | 11,333 | 11.6 K to 11.3 K (-2.60 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 204 | 4,596 | 7,539 | 7.7 K to 7.5 K (-2.63 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 206 | 4,642 | 7,743 | 7.9 K to 7.7 K (-2.59 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 581 | 13,090 | 21,438 | 22 K to 21.4 K (-2.64 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 586 | 13,205 | 22,019 | 22.6 K to 22 K (-2.59 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 29,782 | 670,971 | 1,099,772 | 1.1 M to 1.1 M (-2.64 %) |
| Aug 02 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.53 | 30,045 | 677,022 | 1,129,554 | 1.2 M to 1.1 M (-2.59 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 873 | 19,649 | 11,635 | 12.5 K to 11.6 K (-6.98 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 3 | 68 | 12,508 | 12.5 K to 12.5 K (-0.02 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 270 | 6,075 | 12,511 | 12.8 K to 12.5 K (-2.11 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 596 | 13,414 | 7,949 | 8.5 K to 7.9 K (-6.97 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 3 | 68 | 8,545 | 8.5 K to 8.5 K (-0.04 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 184 | 4,140 | 8,548 | 8.7 K to 8.5 K (-2.11 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 1,696 | 38,172 | 22,605 | 24.3 K to 22.6 K (-6.98 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 6 | 135 | 24,301 | 24.3 K to 24.3 K (-0.02 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 523 | 11,768 | 24,307 | 24.8 K to 24.3 K (-2.11 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 87,010 | 1,958,325 | 1,159,599 | 1.2 M to 1.2 M (-6.98 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 317 | 7,133 | 1,246,609 | 1.2 M to 1.2 M (-0.03 %) |
| Jul 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 26,852 | 604,170 | 1,246,926 | 1.3 M to 1.2 M (-2.11 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 192 | 4,321 | 12,781 | 13 K to 12.8 K (-1.48 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 601 | 13,526 | 12,973 | 13.6 K to 13 K (-4.43 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 132 | 2,971 | 8,732 | 8.9 K to 8.7 K (-1.49 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 411 | 9,250 | 8,864 | 9.3 K to 8.9 K (-4.43 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 374 | 8,417 | 24,830 | 25.2 K to 24.8 K (-1.48 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 1,167 | 26,263 | 25,204 | 26.4 K to 25.2 K (-4.43 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 19,168 | 431,389 | 1,273,778 | 1.3 M to 1.3 M (-1.48 %) |
| Jul 25 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.51 | 59,854 | 1,347,014 | 1,292,946 | 1.4 M to 1.3 M (-4.42 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.52 | 472 | 10,631 | 13,574 | 14 K to 13.6 K (-3.36 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 10 | 225 | 14,046 | 14.1 K to 14 K (-0.07 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 208 | 4,681 | 14,056 | 14.3 K to 14.1 K (-1.46 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.52 | 323 | 7,275 | 9,275 | 9.6 K to 9.3 K (-3.37 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 7 | 158 | 9,598 | 9.6 K to 9.6 K (-0.07 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 142 | 3,196 | 9,605 | 9.7 K to 9.6 K (-1.46 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.52 | 917 | 20,655 | 26,371 | 27.3 K to 26.4 K (-3.36 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 20 | 450 | 27,288 | 27.3 K to 27.3 K (-0.07 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 403 | 9,069 | 27,308 | 27.7 K to 27.3 K (-1.45 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.52 | 46,992 | 1,058,457 | 1,352,800 | 1.4 M to 1.4 M (-3.36 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 1,016 | 22,860 | 1,399,792 | 1.4 M to 1.4 M (-0.07 %) |
| Jul 22 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 22.50 | 20,656 | 464,849 | 1,400,808 | 1.4 M to 1.4 M (-1.45 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 24,111 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 86,487 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 33,108 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 344,662 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 1,236,302 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 473,276 | 0 | 0 | |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | P | 15.00 | 8,173 | 122,595 | 151,879 | 143.7 K to 151.9 K (+5.69 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | P | 15.00 | 116,827 | 1,752,405 | 2,171,067 | 2.1 M to 2.2 M (+5.69 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 24,111 | 0 | 143,706 | 119.6 K to 143.7 K (+20.16 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 86,487 | 0 | 119,595 | 33.1 K to 119.6 K (+261.23 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 33,108 | 0 | 33,108 | 0 to 33.1 K |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 344,662 | 0 | 2,054,240 | 1.7 M to 2.1 M (+20.16 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 1,236,302 | 0 | 1,709,578 | 473.3 K to 1.7 M (+261.22 %) |
| Jul 01 2019 | MORF | Morphic Holding, I ... | Nashat Amir | Director | Buy | C | 0.00 | 473,276 | 0 | 473,276 | 0 to 473.3 K |
| Jun 18 2019 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Option Exercise | A | 2.10 | 10,000 | 21,000 | 10,000 | |
| Jun 12 2019 | SYRS | Syros Pharmaceutic ... | Nashat Amir | Director | Option Exercise | A | 5.60 | 11,000 | 61,600 | 11,000 | |
| May 23 2019 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | A | 21.21 | 10,158 | 215,451 | 10,158 | |
| May 07 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 17.15 | 16,000 | 274,400 | 16,000 | |
| Feb 01 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 463 | 6,558 | 1,473,186 | 1.5 M to 1.5 M (-0.03 %) |
| Feb 01 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 340 | 4,816 | 1,473,649 | 1.5 M to 1.5 M (-0.02 %) |
| Feb 01 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 990 | 14,023 | 1,473,989 | 1.5 M to 1.5 M (-0.07 %) |
| Feb 01 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 51,224 | 725,562 | 1,474,979 | 1.5 M to 1.5 M (-3.36 %) |
| Jan 31 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 941 | 13,326 | 1,526,203 | 1.5 M to 1.5 M (-0.06 %) |
| Jan 31 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 644 | 9,120 | 1,527,144 | 1.5 M to 1.5 M (-0.04 %) |
| Jan 31 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 1,834 | 25,973 | 1,527,788 | 1.5 M to 1.5 M (-0.12 %) |
| Jan 31 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.16 | 94,081 | 1,332,375 | 1,529,622 | 1.6 M to 1.5 M (-5.79 %) |
| Jan 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.78 | 675 | 9,303 | 1,623,703 | 1.6 M to 1.6 M (-0.04 %) |
| Jan 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.78 | 463 | 6,381 | 1,624,378 | 1.6 M to 1.6 M (-0.03 %) |
| Jan 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.78 | 1,316 | 18,138 | 1,624,841 | 1.6 M to 1.6 M (-0.08 %) |
| Jan 30 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.78 | 67,546 | 930,946 | 1,626,157 | 1.7 M to 1.6 M (-3.99 %) |
| Jan 29 2019 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Buy | P | 1.50 | 1,125,756 | 1,688,634 | 2,676,234 | 1.6 M to 2.7 M (+72.61 %) |
| Jan 29 2019 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Buy | P | 1.50 | 11,258 | 16,887 | 26,760 | 15.5 K to 26.8 K (+72.62 %) |
| Jan 29 2019 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Buy | P | 1.50 | 7,711 | 11,567 | 18,329 | 10.6 K to 18.3 K (+72.62 %) |
| Jan 29 2019 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Buy | P | 1.50 | 21,941 | 32,912 | 52,156 | 30.2 K to 52.2 K (+72.62 %) |
| Jan 29 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.14 | 868 | 12,275 | 1,693,703 | 1.7 M to 1.7 M (-0.05 %) |
| Jan 29 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.14 | 595 | 8,414 | 1,694,571 | 1.7 M to 1.7 M (-0.04 %) |
| Jan 29 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.14 | 1,693 | 23,942 | 1,695,166 | 1.7 M to 1.7 M (-0.10 %) |
| Jan 29 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 14.14 | 86,844 | 1,228,122 | 1,696,859 | 1.8 M to 1.7 M (-4.87 %) |
| Jan 23 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.28 | 381 | 6,203 | 1,783,703 | 1.8 M to 1.8 M (-0.02 %) |
| Jan 23 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.28 | 261 | 4,249 | 1,784,084 | 1.8 M to 1.8 M (-0.01 %) |
| Jan 23 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.28 | 743 | 12,097 | 1,784,345 | 1.8 M to 1.8 M (-0.04 %) |
| Jan 23 2019 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.28 | 38,098 | 620,285 | 1,785,088 | 1.8 M to 1.8 M (-2.09 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 323 | 3,958 | 1,823,186 | 1.8 M to 1.8 M (-0.02 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 221 | 2,708 | 1,823,509 | 1.8 M to 1.8 M (-0.01 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 630 | 7,719 | 1,823,730 | 1.8 M to 1.8 M (-0.03 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 32,300 | 395,775 | 1,824,360 | 1.9 M to 1.8 M (-1.74 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 240 | 3,351 | 1,856,660 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.19 | 640 | 8,445 | 1,856,900 | 1.9 M to 1.9 M (-0.03 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 180 | 2,513 | 1,857,540 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.17 | 423 | 5,569 | 1,857,720 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 454 | 6,337 | 1,858,143 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.20 | 1,261 | 16,651 | 1,858,597 | 1.9 M to 1.9 M (-0.07 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 23,023 | 321,364 | 1,859,858 | 1.9 M to 1.9 M (-1.22 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.21 | 64,989 | 858,362 | 1,882,881 | 1.9 M to 1.9 M (-3.34 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 172 | 2,868 | 1,947,870 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 118 | 1,967 | 1,948,042 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 334 | 5,568 | 1,948,160 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 17,164 | 286,160 | 1,948,494 | 2 M to 1.9 M (-0.87 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 4,101 | 68,826 | 1,965,658 | 2 M to 2 M (-0.21 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 2,809 | 47,143 | 1,969,759 | 2 M to 2 M (-0.14 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 7,993 | 134,145 | 1,972,568 | 2 M to 2 M (-0.40 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 410,097 | 6,882,576 | 1,980,561 | 2.4 M to 2 M (-17.15 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 796 | 13,303 | 2,390,658 | 2.4 M to 2.4 M (-0.03 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 546 | 9,125 | 2,391,454 | 2.4 M to 2.4 M (-0.02 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 1,552 | 25,937 | 2,392,000 | 2.4 M to 2.4 M (-0.06 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 79,634 | 1,330,820 | 2,393,552 | 2.5 M to 2.4 M (-3.22 %) |
| Jun 26 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | A | 21.62 | 20,316 | 439,232 | 20,316 | |
| Jun 19 2018 | SELB | SELECTA BIOSCIENCE ... | Nashat Amir | Director | Option Exercise | A | 12.75 | 10,000 | 127,500 | 10,000 | |
| Jun 15 2018 | SYRS | Syros Pharmaceutic ... | Nashat Amir | Director | Option Exercise | A | 12.95 | 11,000 | 142,450 | 11,000 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 47,225 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 808,166 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 115,659 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 1,979,216 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 43,487 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 744,162 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 80,016 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 1,369,259 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 82,363 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 1,409,429 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 55,211 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Option Exercise | C | 0.00 | 944,789 | 0 | 0 | |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | P | 14.00 | 7,887 | 110,418 | 156,395 | 148.5 K to 156.4 K (+5.31 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | P | 14.00 | 134,970 | 1,889,580 | 2,676,311 | 2.5 M to 2.7 M (+5.31 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 16,542 | 0 | 148,508 | 132 K to 148.5 K (+12.54 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 283,090 | 0 | 2,541,341 | 2.3 M to 2.5 M (+12.54 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 40,514 | 0 | 131,966 | 91.5 K to 132 K (+44.30 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 693,294 | 0 | 2,258,251 | 1.6 M to 2.3 M (+44.30 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 15,233 | 0 | 91,452 | 76.2 K to 91.5 K (+19.99 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 260,670 | 0 | 1,564,957 | 1.3 M to 1.6 M (+19.99 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 28,028 | 0 | 76,219 | 48.2 K to 76.2 K (+58.16 %) |
| May 31 2018 | SRRK | Scholar Rock Holdi ... | Nashat Amir | Director | Buy | C | 0.00 | 479,634 | 0 | 1,304,287 | 824.7 K to 1.3 M (+58.16 %) |